Larry, an American patient with advanced gastroesophageal junction adenocarcinoma, traveled from Los Angeles to a hospital in Shenzhen, China, for CAR-T therapy for stomach cancer. Two years of chemotherapy and targeted treatment at home had not stopped his disease. In September 2026 he received a Claudin18.2-targeted CAR-T cell infusion. His tumor marker dropped sharply afterward, and he left the hospital close to complete response.
A diagnosis that kept outrunning treatment
Larry was diagnosed with moderately to poorly differentiated adenocarcinoma of the gastroesophageal junction, the area where the esophagus meets the stomach, about a year and a half before he was admitted to the hospital in Shenzhen. His initial treatment followed a standard sequence. He had chemotherapy before surgery, then surgery itself, then a first-line and a second-line drug regimen.
His last treatment before leaving the United States combined the chemotherapy drug paclitaxel with the targeted antibody ramucirumab. Doctors also delivered paclitaxel directly into his abdominal cavity. The cancer kept progressing anyway. His CA19-9 level climbed to 1,455 U/mL, according to the hospital's account of the case. CA19-9 is a blood marker that tends to rise when this type of tumor is active and fall when treatment is working.
A biopsy of a metastasis in his abdominal lining found that 99% of the tumor cells were positive for Claudin18.2 (hospital report). Claudin18.2 is a protein that some gastric and gastroesophageal cancers display on the surface of their cells. In July 2026, Larry tried zolbetuximab, an antibody that also targets Claudin18.2, combined with chemotherapy. The disease progressed again within weeks. He had also already tried, and lost ground on, chemotherapy combined with immunotherapy and chemotherapy combined with an anti-angiogenic drug.
A biomarker search that led to China
Larry's wife, Jamie, had spent the year since his diagnosis reading about biomarkers relevant to cancer treatment, Claudin18.2 among them. In comments translated from the Chinese coverage of the case, she later described searching online for her husband's specific biomarker paired with his exact cancer type, rather than searching for his diagnosis alone. That search surfaced a treatment option that did not yet exist as an approved product in the United States, a CAR-T cell therapy built for solid tumors expressing Claudin18.2.
Turning that search result into an actual treatment meant more than booking a flight. Before Larry and Jamie left Los Angeles, an English-speaking care coordinator reviewed his full file. That included his pathology report, his treatment history and the Claudin18.2 biopsy result, so the receiving hospital's oncology team could assess whether he was a realistic candidate before he traveled 11,600 kilometers.
The same coordinator worked out the logistics around the trip itself, from flight timing to the paperwork he would need to enter China. They also built a day-by-day plan for admission, pre-treatment testing and the infusion date, set around his medical schedule rather than the other way around. That coordination did not end at the airport. The same point of contact stayed in touch with the couple through the hospital stay in Shenzhen, including the days after the infusion when Larry's symptoms needed monitoring, and after he was discharged.
CAR-T therapy: giving immune cells a target
CAR-T is short for chimeric antigen receptor T-cell therapy. It is a treatment that takes a patient's own T-cells, a type of white blood cell, out of the body and engineers them in a lab to carry a receptor that recognizes a specific protein on cancer cells, in Larry's case Claudin18.2. The modified cells are grown in large numbers outside the body, then infused back into the patient, according to the hospital's description of the process.
Unlike a chemotherapy drug, which the body clears over time, the engineered T-cells can keep multiplying inside the patient. They continue attacking cells that carry the target protein. The hospital's oncology team framed this as a theoretical advantage. A single infusion, rather than a repeating course of treatment, is built to keep working on its own.
The infusion and the days after
Larry received his CAR-T infusion on September 29, 2026. He developed a fever that reached 39°C (about 102°F), along with mild to moderate swelling in both legs and a mild drop in blood pressure, the hospital's report says. The medical team treated him with intravenous fluids and tocilizumab, a drug commonly used to manage cytokine release syndrome. Cytokine release syndrome is an inflammatory reaction some patients have after CAR-T treatment, as the modified immune cells become active throughout the body. Larry's symptoms improved, and the markers his care team was tracking for treatment-related side effects stabilized about ten days after the infusion.
A phase 2 trial of satri-cel, the CAR-T product Larry received, reported cytokine release syndrome in 95.5% of treated patients, with a severe (grade 3 or higher) reaction in 4.5%, per the trial's record on ClinicalTrials.gov. That is in line with what Larry experienced: a reaction that needed treatment but did not become severe.
Results: a tumor marker that fell sharply
Before the infusion, Larry's CA19-9 level had risen to 8,200 U/mL. Follow-up testing afterward showed it had fallen to 57.6 U/mL, and imaging showed his tumor had shrunk substantially, close to what oncologists call a complete response, according to the hospital's report on his case. He was discharged from the hospital.
| Milestone | What happened |
|---|---|
| About 18 months before admission | Diagnosed with gastroesophageal junction adenocarcinoma |
| Before travel to China | Neoadjuvant therapy, surgery, first-line and second-line treatment; disease progresses on paclitaxel plus ramucirumab; CA19-9 reaches 1,455 U/mL |
| July 2026 | Tries zolbetuximab plus chemotherapy; disease progresses again within weeks |
| Before infusion | CA19-9 at 8,200 U/mL |
| September 29, 2026 | CAR-T cell infusion in Shenzhen |
| Days after infusion | Fever to 39°C, leg swelling, mild hypotension; treated with fluids and tocilizumab |
| About 10 days after infusion | Side-effect markers stabilize |
| Follow-up | CA19-9 falls to 57.6 U/mL; tumor shrinks substantially; discharged |
This is one patient's result, reported by his treating hospital. It is not a guarantee of how any other patient with a similar diagnosis would respond. The hospital's own oncology team stressed that the treatment is not appropriate for every gastric or gastroesophageal cancer patient. Before anyone receives it, a pathology test has to confirm Claudin18.2 expression, and a multidisciplinary team has to review the patient's overall health, prior treatment history and risk of side effects.
What CAR-T therapy for stomach cancer in China actually involves, and who qualifies
China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel), developed by CARsgen Therapeutics, on June 22, 2026. The NMPA is China's national drug regulator. OncLive and the Association for the Advancement of Blood and Biotherapies both describe it as the first CAR-T cell therapy approved anywhere for a solid tumor. Earlier CAR-T approvals, in China and elsewhere, were limited to blood cancers such as leukemia and lymphoma.
The approval covers adults with advanced gastric or gastroesophageal junction adenocarcinoma that is Claudin18.2-positive and HER2-negative, and who have already gone through at least two prior lines of therapy that stopped working. That is a narrow eligibility window. It rules out patients earlier in treatment and those whose tumors do not express the target protein.
The approval drew on a randomized phase 2 trial, registered on ClinicalTrials.gov as NCT04581473 and also known as CT041-ST-01. Among 156 patients, satri-cel produced a median progression-free survival of 3.25 months, against 1.77 months for physician's choice treatment. OncLive reported that difference as statistically significant, with a hazard ratio of 0.366.
The therapy is not yet an approved product in the United States, the UK or Gulf countries. Because of that, some international patients with a confirmed Claudin18.2-positive diagnosis travel to China specifically to access it, the way Larry did. Reported costs for CAR-T treatment in China vary by hospital and case. One account citing Wall Street Journal reporting put the range at roughly $150,000 to $230,000, according to ThePrint's coverage of medical travel for this treatment. That is well below US list prices for CAR-T products, though still a significant expense, and it is not a figure Larry's hospital has confirmed for his specific case.
FAQ
What is CAR-T cell therapy for stomach cancer?
CAR-T therapy modifies a patient's own T-cells so they can recognize and attack cancer cells carrying a specific target protein, then returns the modified cells to the body. For stomach and gastroesophageal junction cancer, the approved target in China is Claudin18.2, a protein some tumors express on their surface.
Is CAR-T therapy for solid tumors approved in China?
Yes. China's NMPA approved satricabtagene autoleucel on June 22, 2026, for Claudin18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma in patients who have already had at least two prior lines of therapy. It is reported as the first CAR-T product approved anywhere for a solid tumor.
Does every stomach cancer patient qualify for this treatment?
No. A pathology test has to confirm that the tumor expresses Claudin18.2, and the approval only covers patients who have already progressed through at least two earlier lines of therapy. A multidisciplinary medical team also reviews each patient's overall health and treatment history before deciding whether to proceed.
What side effects can this CAR-T therapy cause?
Reported side effects include fever, swelling and cytokine release syndrome, a systemic inflammatory reaction to the modified immune cells. In Larry's case, doctors managed these with intravenous fluids and tocilizumab, and his symptoms stabilized about ten days after infusion. Hospitals providing this treatment need the staff and equipment to monitor and manage these reactions.
Can international patients get this CAR-T therapy in China?
Patients from countries where the therapy is not yet approved, including the United States, have traveled to China to receive it after a confirmed Claudin18.2-positive diagnosis. Eligibility still depends on meeting the approved indication. Arranging treatment as a foreign patient typically means sending medical records and pathology results to a hospital in advance for review.
Sources
Fact check: the patient narrative, dates and clinical numbers below are drawn from the treating hospital's own published account of the case; the regulatory and trial figures are drawn from the independent outlets linked beside each claim.
- Shenzhen Special Zone Daily / Dutenews, "从洛杉矶到深圳，一位晚期消化道肿瘤患者的寻医之路," republished by the hospital's WeChat account, October 27, 2026. Patient narrative, diagnosis history, treatment details and clinical team commentary are drawn from this report; quotes attributed to the patient's wife are translated from the Chinese text and may not be her exact original wording.
- OncLive, "China's NMPA Approves First CAR T-Cell Therapy for CLDN18.2+/HER2- Advanced Gastric/GEJ Adenocarcinoma" and "Satri-cel NDA Gets Go-Ahead From NMPA in Pretreated CLDN18.2+ Advanced Gastric/GEJ Cancer," 2026.
- Association for the Advancement of Blood and Biotherapies, "China Approves World's First CAR T-Cell Therapy for Solid Tumors," July 1, 2026.
- ClinicalTrials.gov, "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection" (NCT04581473).
- ThePrint, citing Wall Street Journal reporting, "Cancer patients from US, Europe turn to China for cheaper CAR-T treatment."
How Goji Health can help
Goji Health is a US-China operated medical coordination company. We do not diagnose or treat. Our work is everything around the medical care, and for most international patients that starts with communication.
Each patient has one English-speaking care manager from the first message through the end of their stay. That person goes with you to the hospital, makes sure you and your doctors understand each other, and answers at any hour while you are in China. Send us your medical records and we reply within 24-48 hours of receiving the complete file. The patient in this article came to China through Goji Health.
Contact us to send your records for a case review
This article is for general information and is not medical advice. Individual results vary.